OGEN Pengajuan SEC - Oragenics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300639MGD19K4ZW90
CIK	1174940

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Oragenics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 1, 2025 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 1, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
August 26, 2025	S-8	As Filed with the Securities and Exchange Commission on August 25, 2025 As Filed with the Securities and Exchange Commission on August 25, 2025 Registration No.
August 26, 2025	EX-FILING FEES	CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Oragenics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Oragenics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (2)(3) Fee Rate Amount Of Registration Fee Equity Common Stock, par value $
August 26, 2025	EX-4.16	THIRD AMENDMENT TO ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN Exhibit 4.16 THIRD AMENDMENT TO ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN This Plan Amendment to the 2021 Equity Incentive Plan (the “Plan Amendment”) is made pursuant to Section 13 of the 2021 Incentive Plan (the “2021 Plan”). Recitals: WHEREAS, the 2021 Plan was adopted by the Company and approved by the shareholders on February 25, 2022; and WHEREAS, 10,000,000 shares were originally authorize
August 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 11, 2025 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 11, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 11, 2025	EX-99.1	Oragenics Q2 2025 Shareholder Update Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion Exhibit 99.1 Oragenics Q2 2025 Shareholder Update Advancing Brain-First Recovery Platform Toward Clinical Milestones Pioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., August 11, 2025 — Oragenics, Inc. (NYSE American: OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategi
August 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-32188 ORAGENICS, IN
July 2, 2025	EX-4.2	Warrant Agency Agreement. Exhibit 4.2 Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of July 2, 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of July 2, 2025 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”). W I T N
July 2, 2025	EX-1.1	Placement Agency Agreement, dated, July 1, 2025 between Oragenics, Inc. and Dawson James Securities, Inc. Exhibit 1.1 Execution Version PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 July 1, 2025 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement a
July 2, 2025	EX-99.1	Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants Exhibit 99.1 Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants July 1, 2025 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purcha
July 2, 2025	EX-4.1	Form of Series H Preferred Warrant. Exhibit 4.1 SERIES H PREFERRED PURCHASE WARRANT oragenics, inc. Warrant Shares: Initial Exercise Date: July 2, 2025 CUSIP 684023 146 THIS SERIES H PREFERRED PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 2,
July 2, 2025	EX-3.1	Certificate of Designation for Series H Preferred Stock Exhibit 3.1 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority co
July 2, 2025	EX-99.2	Oragenics Completes Approximately $16.5 Million Offering Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury Exhibit 99.2 Oragenics Completes Approximately $16.5 Million Offering Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury SARASOTA, Fla. — July 2, 2025 — Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering intranasal therapeutics for neurological disorders, today announced the successful closing
July 2, 2025	424B5	660,000 Shares of Series H Convertible Preferred Stock 660,000 Warrants to Purchase 660,000 Shares of Series H Convertible Preferred Stock 660,000 shares of Series H Convertible Preferred Stock issuable upon exercise of the Warrants Up to 19,140,000 Filed Pursuant to Rule 424(b)(5) Registration No. 333-288225 660,000 Shares of Series H Convertible Preferred Stock 660,000 Warrants to Purchase 660,000 Shares of Series H Convertible Preferred Stock 660,000 shares of Series H Convertible Preferred Stock issuable upon exercise of the Warrants and Up to 19,140,000 shares of Common Stock Underlying (i) the Series H Convertible Preferred Stock Sold H
July 2, 2025	EX-10.1	Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 2, 2025, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company has filed the Registration Stateme
July 2, 2025	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 30, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
June 30, 2025	EX-10.27	Form of Securities Purchase Agreement Exhibit 10.27 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July [*], 2025, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, the Company has filed the Registration Stat
June 30, 2025	S-1/A	As filed with the Securities and Exchange Commission on June 30, 2025 As filed with the Securities and Exchange Commission on June 30, 2025 Registration No.
June 23, 2025	EX-4.8	Form of Series H Warrant Exhibit 4.8 FORM OF SERIES H PREFERRED PURCHASE WARRANT oragenics, inc. Warrant Shares: Initial Exercise Date: , 2025 THIS SERIES H PREFERRED PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2030 (the “Initial E
June 23, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Oragenics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2)(3) Fee Rate Amount of Registration Fe
June 23, 2025	EX-3.10	Form of Certificate of Designation of Preferences, Rights and Designations of Series H Convertible Preferred Stock Exhibit 3.10 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority c
June 23, 2025	EX-4.9	Form of Warrant Agent Agreement Exhibit 4.9 Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of June , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June , 2025 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”). W I T N E
June 23, 2025	EX-1.1	Form of Placement Agent Agreement Exhibit 1.1 Execution Version PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 June [], 2025 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement
June 23, 2025	S-1	As filed with the Securities and Exchange Commission on June 23, 2025 As filed with the Securities and Exchange Commission on June 23, 2025 Registration No.
June 3, 2025	DRS	As confidentially submitted to the Securities and Exchange Commission on June 2, 2025. This draft registration statement has not been filed publicly with the Securities and Exchange Commission and all information herein remains strictly confidential. As confidentially submitted to the Securities and Exchange Commission on June 2, 2025.
June 3, 2025	EX-1.1	PLACEMENT AGENCY AGREEMENT Exhibit 1.1 Execution Version PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 June [], 2025 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement
June 3, 2025	EX-3.10	ARTICLES OF AMENDMENT ARTICLES OF INCORPORATION ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Exhibit 3.10 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES H CONVERTIBLE PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority c
June 3, 2025	EX-4.9	Oragenics, Inc. Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of June __, 2025 WARRANT AGENCY AGREEMENT Exhibit 4.9 Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of June , 2025 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of June , 2025 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”). W I T N E
June 3, 2025	EX-4.8	FORM OF SERIES H PREFERRED PURCHASE WARRANT oragenics, inc. Exhibit 4.8 FORM OF SERIES H PREFERRED PURCHASE WARRANT oragenics, inc. Warrant Shares: Initial Exercise Date: , 2025 THIS SERIES H PREFERRED PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2030 (the “Initial E
May 28, 2025	EX-3.1	Amendment to Articles of Incorporation to Effectuate Reverse stock Split Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION ORAGENICS, INC. (Document Number P96000091949) Oragenics, Inc. (the “Corporation”), does hereby certify that the Corporation’s Articles of Incorporation originally filed with the Florida Department of State on November 6, 1996, as amended and restated on May 8, 2002, as further amended by those certain amendmen
May 28, 2025	8-K	Material Modification to Rights of Security Holders, Other Events, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 27, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 28, 2025	EX-99.1	Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split Exhibit 99.1 May 28, 2025 Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split SARASOTA, FL. (May 28, 2025) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the “Board”) on May 27, 2025 approved a One-for-Thirty (1-for-30) reverse stock
May 20, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 20, 2025 (Date of earliest event reported) Oragenics, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 20, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 20, 2025	EX-99.1	EX-99.1 Exhibit 99.1
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-32188 ORAGENICS, I
May 2, 2025	EX-10.1	Janet Huffman Employment Agreement Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) dated as of May 2, 2025 (the “Effective Date”), is by and between ORAGENICS, INC., a Florida corporation, (the “Company”), and JANET HUFFMAN (the “Executive”). WHEREAS, the Company is a biotechnology company currently engaged in the business of research, development, and sales of proprietary products
May 2, 2025	8-K	Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 2, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (IR
April 11, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 11, 2025	CORRESP	April 11, 2025 Bank of America Plaza 813.229.7600 101 East Kennedy Boulevard 813.229.1660 fax Suite 2800 Tampa, Florida 33602 julio c. esquivel (813) 227-2325 [email protected] April 11, 2025 Via Edgar Frank Wyman and Angela Connell, Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street Washington, DC 20549 Re: Oragenics, Inc. Form 10-K for the
April 9, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 9, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
April 9, 2025	EX-99.1	Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial Exhibit 99.1 Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial SARASOTA, Fla., Apr. 9, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has submitted a clinical trial protocol for regulatory review to t
April 1, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
March 27, 2025	EX-99.1	Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum Exhibit 99.1 Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry Momentum SARASOTA, Fla., Mar. 27, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditio
March 27, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 27, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
March 19, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
March 14, 2025	EX-10.28	Placement Agency Agreement dated, March 13, 2025, between Oragenics, Inc. and Dawson James Securities, Inc. Exhibit 10.28 Execution Version PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 March 13, 2025 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placeme
March 14, 2025	EX-10.26	Form of Note dated March 13, 2025 Exhibit 10.26 [FORM OF SENIOR NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES AC
March 14, 2025	EX-3.9	Certificate of Designation for Series G Preferred Stock Exhibit 3.9 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES G MIRRORING PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority conf
March 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32188 ORAGENICS, INC. (Exact name
March 14, 2025	EX-10.27	Form of Lock-Up Agreement Exhibit 10.27 ORAGENICS, Inc. - Lock-up Agreement March 13, 2025 Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 Ladies and Gentlemen: The undersigned understands that Oragenics, Inc., a Florida corporation (the “Company”), entered into a Securities Purchase Agreement (the “SPA”) on March 13, 2025 with each purchaser (each, an “Investor”, and collectively “Investors”) identifie
March 14, 2025	EX-10.25	Form of Securities Purchase Agreement Exhibit 10.25 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 13, 2025, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi
March 6, 2025	EX-99.1	Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) Exhibit 99.1 Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) SARASOTA, FL – March. X, 2025 (GLOBE NEWSWIRE) – Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the submission of its Investigator’s Brochure (IB)
March 6, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 6, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
February 18, 2025	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 17, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 5, 2025 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 5, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
February 5, 2025	EX-99.1	Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 Exhibit 99.1 Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025 SARASOTA, Fla., Feb. 5, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Med
February 4, 2025	RW	Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 February 4, 2025 Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 February 4, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Oragenics, Inc. (the “Company”) Request to Withdraw Registration Statement on Form S-1 Filed on December 18, 2024 File No. 333-283927 Ladies and Gent
January 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 21, 2025 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 21, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 21, 2025	EX-99.1	Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO Exhibit 99.1 Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024
January 17, 2025	EX-10.2	Amendment to Executive Employment Agreement between the Company and Janet Huffman dated effective January 16, 2025. Exhibit 10.2 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Amendment”) is effective as of January 16, 2025 (the “Effective Date”), by and between Oragenics, Inc., a Florida corporation (the “Company”), and Janet Huffman (the “Executive”) (Company and Executive may be referred to hereinafter individually, as a “Party” or collectively, as the “Parties”).
January 17, 2025	EX-10.1	Executive Employment Agreement between the Company and Janet Huffman dated effective March 8, 2023. Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) dated as of March 7, 2023 (the “Effective Date”), is by and between ORAGENICS, INC., a Florida corporation, (the “Company”), and JANET HUFFMAN (the “Executive”). WHEREAS, the Company is a biotechnology company currently engaged in the business of research, development, and sales of proprietary product
January 17, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 15, 2025 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction (Commission (IRS Employer of incorporatio
January 14, 2025	CORRESP	Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 January 14, 2025 Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 January 14, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Joseph McCann and Chris Edwards, Division of Corporation Finance Re: Oragenics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 33
January 8, 2025	S-1/A	As filed with the Securities and Exchange Commission on January 7, 2025 As filed with the Securities and Exchange Commission on January 7, 2025 Registration No.
January 8, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Oragenics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2)(3) Fee Rate Amount of Registration Fe
December 31, 2024	S-1/A	As filed with the Securities and Exchange Commission on December 31, 2024 As filed with the Securities and Exchange Commission on December 31, 2024 Registration No.
December 31, 2024	CORRESP	December 31, 2024 Bank of America Plaza 101 East Kennedy Boulevard Suite 2800 Tampa, Florida 33602 813.
December 18, 2024	S-1	As filed with the Securities and Exchange Commission on December 18, 2024 As filed with the Securities and Exchange Commission on December 18, 2024 Registration No.
December 18, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-1 (Form Type) ORAGENICS, INC. (Exact name of Registration as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to be Paid Equit
December 16, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Oragenics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount Of Registration Fee Equity Common Stock, par value $0.001 p
December 16, 2024	S-8	As Filed with the Securities and Exchange Commission on December 16, 2024 As Filed with the Securities and Exchange Commission on December 16, 2024 Registration No.
December 16, 2024	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 11, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
December 16, 2024	EX-4.3	Second Amendment to Equity Incentive Plan. Exhibit 4.3 SECOND AMENDMENT TO ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN This Second Amendment to the 2021 Equity Incentive Plan (the “Second Amendment”) is made pursuant to Section 13 of the 2021 Incentive Plan (the “2021 Plan”). Recitals: WHEREAS, the 2021 Plan was adopted by the Company and approved by the shareholders on February 25, 2022; and WHEREAS, 10,000,000 shares were originally autho
December 16, 2024	EX-99.1	Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference Exhibit 99.1 Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference Sarasota, FL – December 16, 2024 – Oragenics, Inc. (NYSE: OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock.
December 16, 2024	EX-4.3	Second Amendment to 2021 Equity Incentive Plan Exhibit 4.3 SECOND AMENDMENT TO ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN This Second Amendment to the 2021 Equity Incentive Plan (the “Second Amendment”) is made pursuant to Section 13 of the 2021 Incentive Plan (the “2021 Plan”). Recitals: WHEREAS, the 2021 Plan was adopted by the Company and approved by the shareholders on February 25, 2022; and WHEREAS, 10,000,000 shares were originally autho
November 29, 2024	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 26, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
November 14, 2024	SC 13G/A	OGEN / Oragenics, Inc. / Lind Global Fund II LP Passive Investment SC 13G/A 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 684023500 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
November 14, 2024	SC 13G/A	OGEN / Oragenics, Inc. / Iroquois Capital Management, LLC Passive Investment SC 13G/A 1 c110569sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 684023500 (CUSIP Num
November 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Oragenics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedul
November 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC.
October 31, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
October 31, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
October 18, 2024	EX-99.1	Sarasota, FL – October 18, 2024 – Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be h Exhibit 99.1 Oragenics Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit Sarasota, FL – October 18, 2024 – Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 202
October 18, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 18, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
October 16, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 15, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
October 16, 2024	EX-99.1	EX-99.1 EX-99.1 2 ex99-1.htm Exhibit 99.1
October 15, 2024	EX-1.1	At-the-Market Sales Agreement between the Company and Dawson James Securities dated October 11, 2024 Exhibit 1.1 oragenics, INC. COMMON STOCK ATM SALES AGREEMENT October 11, 2024 Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, Fl 33432 Ladies and Gentlemen: Oragenics, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with Dawson James Securities, Inc., as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time
October 15, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 11, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
October 11, 2024	424B5	Up to $10,000,000 Common Stock 424B5 1 form424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 (To Prospectus dated January 25, 2023) Up to $10,000,000 Common Stock Oragenics, Inc. We have entered into an At-The-Market Issuance Sales Agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent” or “Dawson James Securities, Inc.”) relating to the sale of shares of our common stock, pa
October 9, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 9, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
October 9, 2024	EX-99.1	Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation Exhibit 99.1 Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation Sarasota, FL – October 9, 2024 Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company’s progress throughout 2024, including key milestones in the devel
September 20, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Shareholder Director Nominations, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 19, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numb
September 11, 2024	SC 13G	OGEN / Oragenics, Inc. / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 684023500 (CUSIP Number) September 5, 2024 (Date o
September 11, 2024	EX-1	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.
September 5, 2024	EX-4.3	Warrant Agency Agreement. Exhibit 4.3 Oragenics, Inc. and Continental Stock Transfer & Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of September 4, 2024 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of September 4, 2024 (“Agreement”), between Oragenics, Inc., a Florida corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”)
September 5, 2024	424B5	3,078,378 Shares of Common Stock 5,028,206 Pre-Funded Warrants to Purchase 5,028,206 Shares of Common Stock 5,028,206 Shares of Common Stock underlying such Pre-Funded Warrants 405,329 Placement Agent Warrants to Purchase Shares of Common Stock 405,3 Filed Pursuant to Rule 424(b)(5) Registration No. 333-281618 3,078,378 Shares of Common Stock 5,028,206 Pre-Funded Warrants to Purchase 5,028,206 Shares of Common Stock 5,028,206 Shares of Common Stock underlying such Pre-Funded Warrants 405,329 Placement Agent Warrants to Purchase Shares of Common Stock 405,329 Shares of Common Stock Underlying the Placement Agent Warrants This is a reasonable be
September 5, 2024	EX-1.1	Placement Agency Agreement dated, September 4, 2024, between Oragenics, Inc. and Dawson James Securities, Inc. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 September 4, 2024 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement agent (the “Pl
September 5, 2024	EX-10.1	Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [], 2024, between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set
September 5, 2024	EX-4.1	Form of Pre-Funded Warrant. Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK oragenics, inc. Warrant Shares: Initial Exercise Date: September 5, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
September 5, 2024	EX-99.1	Oragenics, Inc. Announces Pricing of Public Offering Exhibit 99.1 Oragenics, Inc. Announces Pricing of Public Offering September 4, 2024 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common st
September 5, 2024	EX-99.2	Oragenics, Inc. Announces Closing of Public Offering Exhibit 99.2 Oragenics, Inc. Announces Closing of Public Offering September 5, 2024 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to
September 5, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 4, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
September 5, 2024	EX-4.2	Form of Placement Agent Warrant. Exhibit 4.2 THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING SEPTEMBER 5,
September 3, 2024	CORRESP	DAWSON JAMES SECURITIES INC. 101 North Federal Highway Suite 600 Boca Raton, Fl 33432 September 3, 2024 DAWSON JAMES SECURITIES INC. 101 North Federal Highway Suite 600 Boca Raton, Fl 33432 September 3, 2024 VIA EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549-3628 Attn: Jimmy McNamara RE: Oragenics, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-281618) (the “Registration Statement”) De
September 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-1 (Form Type) ORAGENICS, INC. (Exact name of Registration as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to be Paid Equit
September 3, 2024	S-1/A	As filed with the Securities and Exchange Commission on September 3, 2024 As filed with the Securities and Exchange Commission on September 3, 2024 Registration No.
September 3, 2024	CORRESP	Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 September 3, 2024 Oragenics, Inc. 1990 Main Street, Suite 750 Sarasota, Florida 34236 September 3, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Jimmy McNamara Re: Oragenics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-281618 Request for Acceleration Dear Mr. McNama
August 21, 2024	EX-99.1	Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients ● Falls and car accidents lead incidence of concussions in emergency departments ● Spray-dried drug Exhibit 99.1 Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients ● Falls and car accidents lead incidence of concussions in emergency departments ● Spray-dried drug formulation allows for easy delivery to patients ● No pharmaceutical treatment is available for concussion; drug, ONP-002, could be first
August 21, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 21, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 21, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 13, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 16, 2024	EX-99.1	Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards Exhibit 99.1 Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards SARASOTA, Fla., August 16, 2024 (GLOBE NEWSWIRE) Oragenics, Inc. (NYSE American: OGEN) (“the Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and key 2
August 16, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-1 (Form Type) ORAGENICS, INC. (Exact name of Registration as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Fees to be Paid Equit
August 16, 2024	S-1	As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No.
August 14, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 14, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 14, 2024	EX-99.1	Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range ● ONP-002 stability suggest no need for cumbersome cold storage ● No FDA-approved pharmaceutical treatment available for concussio Exhibit 99.1 Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range ● ONP-002 stability suggest no need for cumbersome cold storage ● No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., August 14, 2024 (GLOBE NEWSWIRE) Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intrana
August 12, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 12, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 12, 2024	EX-99.1	Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study ● ONP-002 showed no cancer-causing DNA damage ● Phase II clinical trial being planned Exhibit 99.1 Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study ● ONP-002 showed no cancer-causing DNA damage ● Phase II clinical trial being planned SARASOTA, Fla., August 12, 2024 (GLOBE NEWSWIRE) Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, toda
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (Exa
August 9, 2024	EX-10.1	At-The-Market Issuance Sales Agreement between the Company and Ascendiant Capital Markets, LLC dated August 8, 2024 Exhibit 10.1 ORAGENICS, INC. Common Stock (par value $0.001 per share) At-The-Market Issuance Sales Agreement August 8, 2024 Ascendiant Capital Markets, LLC 110 Front Street, Suite 300 Jupiter, FL 33477 Ladies and Gentlemen: Oragenics, Inc., a Florida corporation (the “Company”), confirms its agreement (this “Agreement”) with Ascendiant Capital Markets, LLC (the “Agent”), as follows: 1. Issuance a
August 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 8, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 8, 2024	EX-99.1	Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing ● The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally. Exhibit 99.1 Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing ● The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globally. SARASOTA, Fla., August 8, 2024 (GLOBE NEWSWIRE) Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the trea
July 22, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: July 22, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
July 10, 2024	EX-99.1	Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients Formulation designed to enhance brain uptake Exhibit 99.1 Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients Formulation designed to enhance brain uptake SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has developed a new formulation for its novel
July 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: July 10, 2024 (Date of earliest event reported) Oragenics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: July 10, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
June 26, 2024	EX-99.3	Oragenics, Inc. Announces Closing of Public Offering Exhibit 99.3 Oragenics, Inc. Announces Closing of Public Offering June 26, 2024 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share. The
June 26, 2024	EX-99.2	Oragenics, Inc. Announces Pricing of Public Offering Exhibit 99.2 Oragenics, Inc. Announces Pricing of Public Offering June 25, 2024 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock
June 26, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 25, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
June 26, 2024	EX-1.1	Placement Agency Agreement dated June 25, 2024 between Oragenics, Inc. and Dawson James Securities, Inc. Exhibit 1.1 PLACEMENT AGENCY AGREEMENT Dawson James Securities, Inc. 101 North Federal Highway Suite 600 Boca Raton, FL 33432 June 25, 2024 Ladies and Gentlemen: This letter (this “Agreement”) constitutes the agreement between Oragenics, Inc., a Florida corporation (the “Company”), and Dawson James Securities, Inc. (“Dawson”) pursuant to which Dawson shall serve as the placement agent (the “Placem
June 26, 2024	EX-4.1	Form of Placement Agent Warrant. Exhibit 4.1 THE REGISTERED HOLDER OF THIS COMMON STOCK PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●], 2024, W
June 26, 2024	EX-99.1	Oragenics, Inc. Announces Proposed Public Offering Exhibit 99.1 Oragenics, Inc. Announces Proposed Public Offering June 24, 2024 SARASOTA, FL., June 24, 2024 (GLOBE NEWSWIRE) –Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants i
June 25, 2024	424B5	Up to Shares of Common Stock Pre-Funded Warrants to Purchase up to Shares of Common Stock Up to Shares of Common Stock underlying such Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit
June 25, 2024	424B5	1,100,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 (To Prospectus dated January 25, 2023) 1,100,000 Shares of Common Stock Oragenics, Inc. We are offering on a “reasonable best efforts” basis 1,100,000 shares of our common stock, par value $0.001 per share (the “Common Stock”) at a public offering price of $1.00 per share, pursuant to this prospectus supplement and the accompanying base
June 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 18, 2024 (Date of earliest event reported) Oragenics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 18, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
June 20, 2024	EX-99.1	Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance Exhibit 99.1 Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance June 20, 2024 SARASOTA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June
May 23, 2024	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 23, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 22, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 22, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 22, 2024	EX-99.1	Oragenics Appoints William Exhibit 99.1 Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer Dr. Peacock to Oversee Upcoming Phase II Clinical Trial for Treating Concussion in the Emergency Department SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today an
May 17, 2024	EX-99.2	Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine Exhibit 99.2 Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET. The discussion
May 17, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 17, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 16, 2024	EX-99.1	Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002 for Phase II Concussion Trial Exhibit 99.1 Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002 for Phase II Concussion Trial SARASOTA, Fla., May 16, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today announced an update on the Company and its drug development program. Oragenics is designing an upcomin
May 16, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 16, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
May 15, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (Ex
May 7, 2024	EX-99.1	Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia Exhibit 99.1 Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia (May 7, 2024, Sarasota, FL) - Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Austr
May 7, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: May 7, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (IR
April 22, 2024	EX-99.1	Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards Exhibit 99.1 Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards April 19, 2024 SARASOTA, Fla.—(BUSINESS WIRE)— Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE Amer
April 22, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 18, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
April 16, 2024	8-K	Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 15, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
March 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32188 ORAGENICS, INC. (Exact name
March 29, 2024	EX-4.8	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Oragenics, Inc. (“Oragenics,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following descriptions are summaries of the material terms th
March 29, 2024	EX-97.1	Clawback Policy Exhibit 97.1 ORAGENICS, INC. AMENDED AND RESTATED CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Oragenics, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has, therefore,
March 18, 2024	EX-99.1	Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion Exhibit 99.1 Oragenics Appoints James Kelly MD, Chief Medical Officer to Lead Phase II Clinical Trials for Treating Concussion (March 18, 2024, Sarasota, FL) Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical O
March 18, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 18, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
March 6, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Oragenics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedul
March 6, 2024	SC 13G	OGEN / Oragenics, Inc. / Lind Global Fund II LP Passive Investment SC 13G 1 sch13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 684023500 (CUSIP Number) March 1, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design
March 1, 2024	EX-4.1	Form of Representative’s Warrants. Exhibit 4.1 Form of Representative’s Warrant Agreement WARRANT TO PURCHASE COMMON STOCK ORAGENICS, INC. Warrant Shares: Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
March 1, 2024	EX-99.1	Oragenics Announces Closing of Public Offering Exhibit 99.1 Oragenics Announces Closing of Public Offering SARASOTA, Fla., March 1, 2024 - Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced underwritten public offering of 1,400,000 shares of its c
March 1, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 27, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
March 1, 2024	EX-4.2	Exhibit 4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Oragenics, Inc. (“Oragenics,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following descriptions are summaries of the material terms th
March 1, 2024	EX-1.1	Underwriting Agreement dated February 27, 2024 between Oragenics, Inc. and ThinkEquity LLC. Exhibit 1.1 UNDERWRITING AGREEMENT between ORAGENICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters ORAGENICS, INC. UNDERWRITING AGREEMENT New York, New York February 27, 2024 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 41st Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, Oragenics, Inc., a
February 29, 2024	424B5	The date of this prospectus supplement is February 27, 2024 TABLE OF CONTENTS Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 PROSPECTUS SUPPLEMENT (To Prospectus dated January 25, 2023) 1,400,000 Shares Common Stock Oragenics, Inc. We are offering 1,400,000 shares of our common stock, $0.001 par value per share (the “common stock”), at an offering price of $1.50 per share, pursuant to this prospectus supplement and the accompanying base prospectus. Our common
February 28, 2024	EX-99.1	Oragenics Announces Pricing of Public Offering Exhibit 99.1 Oragenics Announces Pricing of Public Offering SARASOTA, Fla. – February 27, 2024 - Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced the pricing of an underwritten public offering of 1,400,000 shares of its common stock at a
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 27, 2024 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 27, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 28, 2024	EX-99.1	Oragenics Announces Proposed Public Offering Exhibit 99.1 Oragenics Announces Proposed Public Offering SARASOTA, Fla. – [February 27, 2024] – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants to p
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 27, 2024 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 27, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 27, 2024	424B5	The date of this prospectus supplement is , 2024 TABLE OF CONTENTS Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit
February 27, 2024	FWP	FWP
February 12, 2024	EX-99.1	Oragenics, Inc. Announces Leadership Transition Exhibit 99.1 Oragenics, Inc. Announces Leadership Transition (February 12, 2024, Sarasota, FL) Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company’s Chief Executive Officer, entered i
February 12, 2024	SC 13D	OGEN / Oragenics, Inc. / Odyssey Health, Inc. - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Oragenics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) Common Stock 684023302 (CUSIP Number) Odyssey Health, Inc. Joseph M. Redmond 2300 West Sahara Avenue Suite 800 - #4012 Las Vegas, NV 89102 (702) 780-6
February 12, 2024	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 12, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 7, 2024	EX-99.1	Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement Exhibit 99.1 Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement SARASOTA, Fla.—(BUSINESS WIRE)—Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that its engagement agreement with its investment bank has expired and that it does not inte
February 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 7, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 7, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
February 5, 2024	EX-99.1	Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion Exhibit 99.1 Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion February 05, 2024 SARASOTA, Fla.—(BUSINESS WIRE)—Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced it is preparing for a Phase II clinical trial using its novel drug - device combina
February 5, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 5, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 5, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 23, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 23, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 23, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 23, 2024	EX-99.1	Oragenics Announces Termination of At-The-Market Offering Program Exhibit 99.1 Oragenics Announces Termination of At-The-Market Offering Program January 23, 2024 TAMPA, Fla.—(BUSINESS WIRE) — Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) today announced it has terminated its previously announced “at-the-market” (“ATM”) equity offering program. The Company has initiated the 5-day termination process of the ATM offering, with the termination
January 16, 2024	424B5	ThinkEquity The date of this prospectus supplement is , 2024 TABLE OF CONTENTS Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit
January 16, 2024	FWP	FWP
January 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 16, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 16, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 10, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-8 (Form Type) Oragenics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount Of Registration Fee Equity Common Stock, par value $0.001 p
January 10, 2024	S-8	As Filed with the Securities and Exchange Commission on January 10, 2024 As Filed with the Securities and Exchange Commission on January 10, 2024 Registration No.
January 2, 2024	EX-99.1	Adds Clinical-Stage Product Pipeline, Expands Intranasal Drug Delivery Technologies, Names Michael Redmond as President of Oragenics Exhibit 99.1 Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets January 02, 2024 Adds Clinical-Stage Product Pipeline, Expands Intranasal Drug Delivery Technologies, Names Michael Redmond as President of Oragenics TAMPA, Fla.-(BUSINESS WIRE)- Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announces it has completed its previously announced acquisition of
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 2, 2024 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 2, 2024 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
December 29, 2023	EX-10.1	Executive Employment Agreement for Mr. Redmond dated December 28, 2023 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) dated as of December 28, 2023 (the “Effective Date”), is by and between ORAGENICS, INC., a Florida corporation, (the “Company”), and JOSEPH MICHAEL REDMOND (the “Executive”). WHEREAS, the Company is a biotechnology company currently engaged in the business of research, development, and sales of propri
December 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 28, 2023 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 28, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 14, 2023 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 14, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
December 15, 2023	EX-4.2	First Amendment to 2021 Equity Incentive Plan Exhibit 4.2 AMENDMENT TO ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN This Amendment to the 2021 Equity Incentive Plan (the “2021 Incentive Plan”) is made pursuant to Section 13 of the 2021 Incentive Plan. Recitals: WHEREAS, the 2021 Incentive Plan was adopted by the Company and approved by the shareholders on February 25, 2022; WHEREAS, 10,000,000 shares were originally authorized to be issued unde
December 15, 2023	EX-3.1	Amendment to Articles of Incorporation to Increase Common Stock Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION ORAGENICS, INC. (Document Number P96000091949) Oragenics, Inc. (the “Corporation”), does hereby certify that the Corporation’s Articles of Incorporation originally filed with the Florida Department of State on November 6, 1996, as amended and restated on May 8, 2002, as further amended by those certain amendmen
December 15, 2023	EX-4.1	2021 Equity Incentive Plan. Exhibit 4.1 2021 EQUITY INCENTIVE PLAN ORAGENICS, INC. 2021 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given a
December 8, 2023	EX-3.1	Amendment to Articles of Incorporation for Certificate of Designation of Series F Convertible Preferred Stock Exhibit 3.1 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES F CONVERTIBLE PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority co
December 8, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: December 4, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
November 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 20, 2023 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 20, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
November 20, 2023	EX-99.1	Oragenics 2023 Presentation Exhibit 99.1
November 16, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC.
November 2, 2023	EX-99.1	Oragenics Issues Update to Shareholders Exhibit 99.1 Oragenics Issues Update to Shareholders TAMPA, Fla. (November 2, 2023) – Fellow Shareholders, As our annual meeting date approaches and in response to valuable feedback from our shareholders, I believe it important to highlight and summarize some of the information in our proxy statement regarding the proposed increase in our authorized shares as well as our cost-saving efforts. Odyss
November 2, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: November 2, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
November 2, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
October 30, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini
October 30, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
October 10, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defini
October 5, 2023	EX-99.1	Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate Gains Nasal Delivery Technologies and Expands Product Pipeline Exhibit 99.1 Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate Gains Nasal Delivery Technologies and Expands Product Pipeline TAMPA, Fla. and LAS VEGAS, Nev. (October 5, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY) (“Odyssey”) announce the signing of a definitive agr
October 5, 2023	EX-2.1	Asset Purchase Agreement Exhibit 2.1 ASSET Purchase Agreement by and among Oragenics Corporation and Odyssey Health, Inc. f/k/a Odyssey Group International, INC. And Joseph Michael Redmond And Christine Farrell October 4, 2023 TABLE OF CONTENTS Page Article 1 SALE OF ASSETS 1 Section 1.1. Purchase and Sale of Assets 1 Section 1.2. Excluded Assets 3 Section 1.3. Assumed Liabilities 4 Section 1.4. Excluded Liabilities 4 Sec
October 5, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 4, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
October 5, 2023	8-K	Other Events, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: October 4, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
September 29, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 26, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numb
September 29, 2023	EX-99.1	Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets Potential to Protect Against Dental Caries, a Global Health Issue Exhibit 99.1 Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets Potential to Protect Against Dental Caries, a Global Health Issue TAMPA, Fla. (September 29, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Lantern Bioworks announce a groundbreaking partnership, marked by the formalization of a materials transfer agreement. This mile
September 15, 2023	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: September 13, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numb
August 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 18, 2023 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 18, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 18, 2023	EX-16.1	Letter from Mayer Hoffman McCann P.C. dated August 18, 2023. Exhibit 16.1 August 18, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the disclosure set forth in Item 4.01 “Changes in Registrant’s Certifying Accountant” of Oragenics, Inc.’s Current Report on Form 8-K dated August 18, 2023 (the “Current Report”) and are in agreement with the disclosure in the Current Report, insofar as it pertains to
August 11, 2023	EX-10.6	Three-Way Collaborative Research Agreement* Exhibit 10.6 [***] PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(2) OF REGULATIONS S-K AS (I) NOT MATERIAL AND (II) LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE COMPANY HEREBY UNDERTAKES TO FURNISH UNREDACTED COPIES OF THIS EXHIBIT UPON REQUEST BY THE SECURITIES AND EXCHANGE COMMISSION; PROVIDED, HOWEVER, THAT THE COMPANY MAY REQUEST CONFIDENTIAL TREATMENT PURS
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (Exa
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 8, 2023 (Date of earliest event reported) Oragenics, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 8, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
August 10, 2023	EX-10.1	Form of Restricted Stock Award Agreement Exhibit 10.1 FORM OF ORAGENICS, INC. RESTRICTED STOCK AWARD GRANT NOTICE Oragenics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of shares specified and on the terms set forth below in consideration of your services (the “Award”). Your Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2021 Equity Incentive Plan (the “Plan”) and t
August 7, 2023	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 4, 2023 (the “Effective Date”), between Oragenics, Inc., a Florida corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms
August 7, 2023	EX-3.1	Certificate of Designation Exhibit 3.1 ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION OF ORAGENICS, INC. CERTIFICATE OF DESIGNATION AND RIGHTS OF SERIES E MIRRORING PREFERRED STOCK Pursuant to Section 607.0602 of the Florida Business Corporation Act Oragenics, Inc., a corporation organized and existing under the laws of the State of Florida (the “Corporation”), does hereby certify: FIRST: That pursuant to authority conf
August 7, 2023	EX-99.1	ORAGENICS, INC. ANNOUNCES PRIVATE PLACEMENT Exhibit 99.1 ORAGENICS, INC. ANNOUNCES PRIVATE PLACEMENT TAMPA, FL, (August 7, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), biotech company dedicated to fighting infectious diseases including coronaviruses, today announced it has entered into definitive agreements with two healthcare-focused investors, in which the Company issued in a private placement (the “Privat
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 7, 2023 (Date of earliest event reported) Oragenics, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: August 7, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
June 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 5, 2023 (Date of earliest event reported) Oragenics, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: June 5, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (I
June 5, 2023	EX-99.1	Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM Exhibit 99.1 Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM TAMPA, Fla. (June 5, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, announces the award of a grant from CQDM, a Canadian bioresearch consortium, for the co
May 12, 2023	EX-10.7	NRC Technology License Amendment 5 (dated April 3, 2023)* Exhibit 10.7 [***] PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(2) OF REGULATIONS S-K AS (I) NOT MATERIAL AND (II) LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE COMPANY HEREBY UNDERTAKES TO FURNISH UNREDACTED COPIES OF THIS EXHIBIT UPON REQUEST BY THE SECURITIES AND EXCHANGE COMMISSION; PROVIDED, HOWEVER, THAT THE COMPANY MAY REQUEST CONFIDENTIAL TREATMENT PURS
May 12, 2023	EX-10.5	Inspirevax License Agreement* Exhibit 10.5 [***] PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED PURSUANT TO ITEM 601(B)(2) OF REGULATIONS S-K AS (I) NOT MATERIAL AND (II) LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE COMPANY HEREBY UNDERTAKES TO FURNISH UNREDACTED COPIES OF THIS EXHIBIT UPON REQUEST BY THE SECURITIES AND EXCHANGE COMMISSION; PROVIDED, HOWEVER, THAT THE COMPANY MAY REQUEST CONFIDENTIAL TREATMENT PURS
May 12, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (Ex
April 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-32188 ORAGENICS, INC. (Exact name
April 17, 2023	EX-4.9	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference as Exhibit 4.9 to Form 10-K filed on April 17, 2023). Exhibit 4.9 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Oragenics, Inc. (“Oragenics,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock. DESCRIPTION OF CAPITAL STOCK The following descriptions are summaries of the material terms th
April 14, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (E
April 14, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, IN
April 14, 2023	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32188 ORAGENICS, INC. (
April 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 4, 2023 (Date of earliest event reported) Oragenics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 4, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
April 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 3, 2023 (Date of earliest event reported) Oragenics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: April 3, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
April 3, 2023	EX-99.1	World Vaccine Congress 2023 Presentation Exhibit 99.1
March 31, 2023	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-32188 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: .
March 14, 2023	EX-99.1	Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE Potentially Addresses Life-Threatening Antibiotic-Resistant Infections Exhibit 99.1 Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE Potentially Addresses Life-Threatening Antibiotic-Resistant Infections TAMPA, Fla. (March 14, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party labora
March 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 14, 2023 (Date of earliest event reported) Oragenics, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 14, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number)
March 8, 2023	EX-99.1	Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team Exhibit 99.1 Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team TAMPA, Fla. (March 8, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. H
March 8, 2023	EX-10.1	Executive Employment Agreement between the Company and Janet Huffman dated effective March 8, 2023. + Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) dated as of March 7, 2023 (the “Effective Date”), is by and between ORAGENICS, INC., a Florida corporation, (the “Company”), and JANET HUFFMAN (the “Executive”). WHEREAS, the Company is a biotechnology company currently engaged in the business of research, development, and sales of proprietary product
March 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 7, 2023 (Date of earliest event reported) Oragenics, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: March 7, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number) (
March 1, 2023	EX-99.1	Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate Licensing milestones provides opportunity to expand vaccine program Exhibit 99.1 Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate Licensing milestones provides opportunity to expand vaccine program TAMPA, Fla. (March 1, 2023) Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced tha
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 23, 2023 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 23, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 24, 2023	424B5	Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269225 PROSPECTUS SUPPLEMENT (To Prospectus dated January 13, 2020) $5,000,000 Common Stock This prospectus supplement relates to the issuance and sale of shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $5.0 million, from time to time solely through Ladenburg Thalmann & Co. Inc., as exclusive
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 24, 2023 (Date of earliest event reported) Oragenics, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 24, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Numbe
February 24, 2023	EX-1.1	At the Market Offering Agreement dated February 24, 2023, by and among Oragenics, Inc. and Ladenburg Thalmann & Co. Inc.* Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT February 24, 2023 Ladenburg Thalmann & Co. Inc. 640 Fifth Avenue, 4th Floor New York, NY 10019 Ladies and Gentlemen: Oragenics, Inc., a corporation organized under the laws of Florida (the “Company”), confirms its agreement (this “Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Manager”) as follows: 1. Definitions. The terms that follow, when used
February 3, 2023	EX-99.1	Oragenics, Inc. Regains Compliance with NYSE American Exhibit 99.1 February 3, 2023 Oragenics, Inc. Regains Compliance with NYSE American TAMPA, FL. (February 3, 2023) – Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has
February 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 1, 2023 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: February 1, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 20, 2023 (Date of earliest event reported) Oragenics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Date of Report: January 20, 2023 (Date of earliest event reported) Oragenics, Inc. (Exact name of registrant as specified in its charter) FL 001-32188 59-3410522 (State or other jurisdiction of incorporation) (Commission File Number
January 23, 2023	CORRESP	Oragenics, Inc. 4902 Eisenhower Boulevard, Suite Tampa, Florida 33634 January 23, 2023 CORRESP 1 filename1.htm Oragenics, Inc. 4902 Eisenhower Boulevard, Suite Tampa, Florida 33634 January 23, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Lauren Hamill Re: Oragenics, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-269225 Request for Accelerat
January 23, 2023	EX-4.1	Specimen Stock Certificate Exhibit 4.1
January 23, 2023	EX-3.1	Articles of Amendment to Amended and Restated Articles of Incorporation Exhibit 3.1 ARTICLES OF AMENDMENT TO THE AMENDED AND RESTATED ARTICLES OF INCORPORATION ORAGENICS, INC. Oragenics, Inc. (the “Corporation”), does hereby certify that the Corporation’s Articles of Incorporation originally filed with the Florida Department of State on November 6, 1996, as amended and restated on May 8, 2002, as further amended by those certain amendments filed October 28, 2009, Sept
January 13, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 ex107.htm CALCULATION OF REGISTRATION FEE Exhibit 107 CALCULATION OF REGISTRATION FEE Form S-3 (Form Type) ORAGENICS, INC. (Exact name of Registration as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggrega
January 13, 2023	S-3	As filed with the Securities and Exchange Commission on January 13, 2023 As filed with the Securities and Exchange Commission on January 13, 2023 Registration No.
December 23, 2022	EX-99.1	Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split Exhibit 99.1 December 23, 2022 Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split TAMPA, FL. (December 23, 2022) ? Oragenics, Inc. (NYSE American: OGEN) (?Oragenics? or the ?Company?), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors (the ?Board?) on December 22, 2022 approved a 1-for-60 reverse stock split of the

OGEN / Oragenics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings